Aisling Capital Management LP
Aisling Capital Management LP reported 14 US-listed holdings worth $471.6 million in its 13F for the quarter ended 30 June 2026, filed 13 August 2026. Its largest: Bridgebio Pharma Inc. (72.5%), Monte Rosa Therapeutics Inc. (8.0%) and Syndax Pharmaceuticals Inc. (6.1%). Against the quarter before, it opened 1 position, added to 0, trimmed 1 and sold out of 0.
The 14 largest of its 14 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +202.9% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 1
- VTV Therapeutics Inc. Class A New VTVT$1.9 million
Trimmed 1
- Bridgebio Pharma Inc. BBIO-500,000 shares · -10%
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Bridgebio Pharma Inc. BBIO | 4.6M | $341.8 million | 72.48% | -500.0K |
| Monte Rosa Therapeutics Inc. GLUE | 1.6M | $37.6 million | 7.98% | no change |
| Syndax Pharmaceuticals Inc. SNDX | 1.3M | $28.8 million | 6.10% | no change |
| Compass Pathways PLC CMPS | 1.4M | $20.3 million | 4.30% | no change |
| Bicara Therapeutics Inc. BCAX | 568.9K | $16.9 million | 3.58% | no change |
| Bridgebio Oncology Therapeutics Ord BBOT | 1.0M | $7.8 million | 1.64% | no change |
| Scholar Rock Holding Corporation SRRK | 77.0K | $4.2 million | 0.90% | no change |
| Urogen Pharma Ltd URGN | 108.0K | $4.0 million | 0.84% | no change |
| Biomea Fusion Inc. BMEA | 2.0M | $3.0 million | 0.64% | no change |
| Aclaris Therapeutics Inc. ACRS | 434.5K | $2.3 million | 0.49% | no change |
| Eupraxia Pharmaceuticals Inc. EPRX | 325.0K | $2.1 million | 0.46% | no change |
| VTV Therapeutics Inc. Class A New VTVT | 50.0K | $1.9 million | 0.40% | new |
| Marker Therapeutics Inc. MRKR | 325.4K | $478,293 | 0.10% | no change |
| Onkure Therapeutics Inc OKUR | 88.6K | $404,048 | 0.09% | no change |